NCT01785108View on ClinicalTrials.gov

DIABGAD - Trial to Preserve Insulin Secretion in Type 1 Diabetes Using GAD-Alum (Diamyd) in Combination With Vitamin D and Ibuprofen

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Diabetes Mellitus, Type 1
Interventions
BIOLOGICAL

GAD-Alum (Diamyd) 20 µg

BIOLOGICAL

GAD-Alum (Diamyd) 20 µg X 2

DRUG

Vitamin D

DRUG

Ibuprofen

Trial Locations (10)

SE-301 85

Halmstad Hospital, Halmstad

SE-141 86

Astrid Lindgren Children's Hospital - Huddinge, Huddinge

SE-391 85

Kalmar Hospital, Kalmar

SE-581 85

Linköping University, Linköping

SE-221 85

Lund University Hospital, Lund

SE-205 02

Skåne University Hospital, UMAS, Malmo

SE-701 85

Örebro University Hospital, Örebro

SE-118 83

Sachsska, Södersjukhuset, Stockholm

SE-171 76

Astrid Lindgren Children's Hospital, Stockholm

SE-451 80

Uddevalla Hospital, Uddevalla

Sponsors

Collaborators (1)

Diamyd Medical AB
All Listed Sponsors
collaborator

Swedish Child Diabetes Foundation

OTHER

collaborator

The Research Council of South East Sweden (FORSS)

UNKNOWN

collaborator

Diamyd Medical AB

INDUSTRY

lead

Johnny Ludvigsson

OTHER_GOV

NCT01785108 - DIABGAD - Trial to Preserve Insulin Secretion in Type 1 Diabetes Using GAD-Alum (Diamyd) in Combination With Vitamin D and Ibuprofen | Biotech Hunter | Biotech Hunter